Business Context and Reporting Period
This Form 8-K Current Report was filed by Becton, Dickinson and Company (BD) on July 19, 2026. The filing primarily addresses executive leadership changes and organizational restructuring within the company's operating segments.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and personnel matters rather than financial performance data.
Material Changes
- Executive Departure: Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments, announced his intention to retire effective July 19, 2026.
- Transition Plan: Dr. Garrison will remain in his current role through the end of the fiscal year to ensure a smooth transition.
- Organizational Restructuring: To streamline the operating model, the BioPharma Systems segment will now report directly to Thomas E. Polen, Chairman, CEO, and President of BD.
- Succession Search: A comprehensive search is underway to identify the next President of the Medical Essentials segment.
Guidance, Outlook, and Risks
The filing references a press release issued on July 22, 2026, regarding these matters (Exhibit 99.1). No specific financial guidance, forward-looking projections, or new risk factors were disclosed in the text of this 8-K. The primary contingency noted is the ongoing search for a successor to lead the Medical Essentials segment.
Investor Verification Checklist
- Verify the timeline for the search and appointment of the new President of the Medical Essentials segment.
- Confirm the specific reporting date for the end of the current fiscal year to understand Dr. Garrison's exact departure date.
- Review the attached press release (Exhibit 99.1) for any additional details on the transition strategy not included in the 8-K summary.
- Monitor future filings for any impact of this leadership change on segment performance or strategic direction.